Influência da transfusão sanguínea no desenvolvimento de infecção em pacientes com neoplasias malignas do sistema digestório

BACKGROUND: Anemia affects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment. AIM: To determine the influence of the allogeneic blood transfusion as a possible related factor to infection in patients with malignant neoplasms of the gastrointestinal system. PATIENTS AND METHOD: Charts of 400 oncological patients were randomly selected and divided into two groups: group 1 (n = 200) - patients submitted to allogeneic blood transfusion and group 2 (n = 200) - non transfused patients. Both groups were evaluated and compared according to the presence and type of infection and a possible association with age, sex, types of tumors and therapeutics approach. RESULTS: The relation between infection and blood transfusion, as well as age, sex, management and type of presented tumors were not significant. There was no difference in the incidence of infection between the non transfused patients (28) and those submitted to allogeneic blood transfusion (31). CONCLUSIONS: In the present investigation allogeneic blood transfusion was apparently not related to development of infection in patients with malignant gastrointestinal tumors.

[1]  C. Silliman,et al.  Transfusion-related acute lung injury. , 2005, Blood.

[2]  A. Petroianu,et al.  [Influence of blood transfusion on development of infection in patients with malignant neoplasms of the digestive system]. , 2006, Arquivos de Gastroenterologia.

[3]  C. Silliman,et al.  Transfusion-related acute lung injury. , 2005, Blood.

[4]  P. Marik,et al.  Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. , 2005, Chest.

[5]  P. Rouger.  Transfusion induced immunomodulation: myth or reality? , 2004, Transfusion Clinique et Biologique.

[6]  Chris A Rogers,et al.  Effect of autologous salvaged blood on postoperative natural killer cell precursor frequency , 2004, The Lancet.

[7]  A. Shander.  Emerging risks and outcomes of blood transfusion in surgery. , 2004, Seminars in hematology.

[8]  H. Osugi,et al.  Immunologic Effects of Allogeneic versus Autologous Blood Transfusion in Patients Undergoing Radical Oesophagectomy , 2003, European Surgical Research.

[9]  M. Blajchman.  Immunomodulation and Blood Transfusion , 2002, American journal of therapeutics.

[10]  J. Birkmeyer,et al.  Safety of the Blood Supply in the United States: Opportunities and Controversies , 1997, Annals of Internal Medicine.

[11]  N. Blumberg,et al.  Allogeneic transfusion and infection: economic and clinical implications. , 1997, Seminars in hematology.

[12]  Y. Vanrenterghem,et al.  Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. , 1997, Transplantation.

[13]  M. Girolamo,et al.  Relationship of blood transfusion, post-operative infections and immunoreactivity in patients undergoing surgery for gastrointestinal cancer. , 1997, Haematologica.

[14]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[15]  C. Manno.  What's new in transfusion medicine? , 1996, Pediatric clinics of North America.

[16]  J. Jeekel.  Autologous blood donation and epoetin alfa in cancer surgery. , 1996, Seminars in hematology.

[17]  A. Petroianu,et al.  Comparative Incidence of Allergy in the Presence or Absence of Cancer , 1995, The Journal of international medical research.

[18]  L. Aledort,et al.  Transfusion requirements, risks, and costs for patients with malignancy , 1995, Transfusion.

[19]  H. J. Nielsen,et al.  Detrimental effects of perioperative blood transfusion , 1995, The British journal of surgery.

[20]  W. Judd.  Controversies in transfusion medicine , 1995 .

[21]  R. Means.  Erythropoietin in the treatment of anemia in chronic infectious, inflammatory, and malignant diseases , 1995, Current opinion in hematology.

[22]  M. Blajchman,et al.  Mechanisms of transfusion-associated immunosuppression. , 1994, Current opinion in hematology.

[23]  C. Falkson,et al.  Recombinant human erythropoietin in the treatment of cancer-related anaemia. , 1994, Oncology.

[24]  K. Sikora,et al.  Immune modulation and cancer. , 1991, British medical bulletin.

[25]  P. Guillou.  The immunological status of the cancer patient. , 1989, Current opinion in immunology.

[26]  E. Yunis,et al.  Modulation of allogeneic stimulation in man. I. Characterization of an in vitro induced suppressor macrophage population. , 1981, Human immunology.

[27]  A. Kluge,et al.  Blood transfusion-induced suppression of cellular immunity in man. , 1980, Human immunology.

[28]  P. Terasaki,et al.  PROLONGATION EFFECT OF BLOOD TRANSFUSIONS ON KIDNEY GRAFT SURVIVAL , 1976, Transplantation.